Physician profile
Bisher Akil
NPI 1649359555
$479,580.88
in general payments reported to CMS, 2019-2025
8 companies · $27K in 2025
The $27K reported for 2025 was more than what 96% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $103K · 2020: $74K · 2021: $5,594 · 2022: $65K · 2023: $97K · 2024: $108K · 2025: $27K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $188K · Travel and Lodging: $32K · Consulting Fee: $6,663 · Food and Beverage: $5,243.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $187,525.00 |
| Travel and Lodging | $32,421.04 |
| Consulting Fee | $6,662.50 |
| Food and Beverage | $5,242.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $475,549.97 | 2019-2025 | Dovato, Rukobia, Apretude |
| Theratechnologies INC. | $2,500.00 | 2022 | |
| Glaxosmithkline, LLC. | $1,318.45 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $125.00 | 2025 | Rexulti |
| Merck Sharp & Dohme LLC | $34.36 | 2024 | |
| Gilead Sciences, INC. | $29.68 | 2025 | |
| Lilly USA, LLC | $23.42 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bisher Akil listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.